Login to Your Account

After ACS stumble, Cerenis finds path in two orphan indications

By Nuala Moran
Staff Writer

Wednesday, September 3, 2014
LONDON – After failing to reach the primary endpoint in a 507-patient phase IIb trial in acute coronary syndrome (ACS), Cerenis Therapeutics SA has found a route forward for its CER-001 recombinant high-density lipoprotein (HDL), securing orphan drug status in two variants of an inherited rare disorder that causes HDL deficiency.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription